Tempus AI, Inc. (TEM)
Summary
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus AI: Taking Advantage Of Investor Myopia
Tempus AI is a precision medicine leader leveraging AI and a unique data estate, with significant partnerships and a rapidly growing contract backlog exceeding $1 billion. TEM's recent share price decline and controversy around profitability have compressed valuation, creating an attractive entry point for risk-tolerant investors seeking positive alpha. Data licensing revenues rose nearly 70% last quarter, with foundation models and AI-driven products fueling high-margin growth and reinforcing TEM's competitive moat.
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Tempus AI, Inc. is positioned as a data-driven precision medicine leader, leveraging AI and a vast multi-modal patient database to drive diagnostics and biopharma partnerships. TEM's dual business model—genomic diagnostics and data licensing—creates network effects, with diagnostics feeding a proprietary data moat that underpins high-margin, scalable growth. Despite a 50% share price decline from highs and ongoing unprofitability, TEM's rising revenues, expanding gross margins, and robust contract pipeline support a strong buy rating for long-term investors.
Tempus AI, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DD Damir Durkovic Entropy Technologies, LP | 55,432 | $3.27M | $2.63M | -$639,685.4 | -19.54% |
| AS Alexandra Stickelman Root Financial Partners, LLC | 5 | $226 | $237.55 | $11.55 | 5.11% |
| JO Joe-Ben O'Banion TITLEIST ASSET MANAGEMENT, LLC | 59,595 | $3.23M | $2.83M | -$400,392.63 | -12.39% |
| NRG Nemes Rush Group LLC Nemes Rush Group LLC | 1,200 | $64,008 | $57,012 | -$6,996 | -10.93% |
| DB Driton Bilali Ilex Capital Partners (UK) LLP | 454,217 | $20.54M | $21.58M | $1.04M | 5.06% |
Tempus AI, Inc. (TEM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tempus AI, Inc. ever had a stock split?
Tempus AI, Inc. Profile
| Technology Hardware, Storage & Peripherals Industry | Information Technology Sector | Eric Lefkofsky CEO | NASDAQ (NGS) Exchange | 88023B103 CUSIP |
| US Country | 2,400 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tempus AI, Inc. stands as a vanguard healthcare technology company, specializing in delivering cutting-edge diagnostic solutions. Established in 2015 and based in Chicago, Illinois, its operations encompass a comprehensive range of molecular and anatomic pathology tests. Initially known as Tempus Labs, Inc., the company underwent a rebranding to Tempus AI, Inc. in January 2023. Its offerings are designed to support healthcare providers, pharmaceutical entities, biotechnology firms, researchers, and other third-party organizations. Its mission revolves around the fusion of clinical data and artificial intelligence to forge advancements in healthcare outcomes.
Products and Services
Tempus AI, Inc. has curated a diverse portfolio of products and services, each tailored to address various aspects of healthcare diagnostics and research:
- Next Generation Sequencing Diagnostics: Leveraging comprehensive genomic profiling to aid in the identification of DNA mutations responsible for cancers, guiding personalized treatment plans.
- Polymerase Chain Reaction (PCR) Profiling: Enabling rapid detection and identification of genetic material from a specific organism, useful in diagnosing infectious diseases, among others.
- Molecular Genotyping: Provides essential data for understanding genetic predispositions to diseases, facilitating preventive healthcare strategies.
- Insights: Offers a vast library of de-identified clinical, molecular, and imaging data, coupled with a suite of analytical services. It provides pharmaceutical and biotechnology companies with valuable data analytics capabilities, by employing advanced analytical and cloud-compute technologies.
- Trials: A service designed to match clinical trials with suitable candidates, thus accelerating the drug development process for pharmaceutical companies.
- Next; Algos: This suite presents algorithmic tests specifically in the field of oncology, enhancing the speed and accuracy of cancer diagnosis and treatment planning.
- Hub: A comprehensive platform for healthcare providers, facilitating easy ordering, management, and receipt of tests and patient results through both desktop and mobile interfaces.
- Lens: Exclusively for researchers and scientists, this platform allows the exploration, access, and analysis of Tempus's rich data sets, fostering innovation in medical research.
